Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 116, Issue 1, Pages 17-29
Publisher
Wiley
Online
2014-07-21
DOI
10.1111/bju.12867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
- (2014) J-L Lee et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
- (2014) Amir Goldkorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
- (2014) Jeffrey B. Smerage et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501)
- (2013) Michael T. Schweizer et al. CANCER
- Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
- (2013) R. Ferraldeschi et al. CLINICAL CANCER RESEARCH
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- (2013) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms
- (2013) Aurelius Omlin et al. EUROPEAN UROLOGY
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study
- (2013) Robert J. van Soest et al. EUROPEAN UROLOGY
- The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
- (2013) Gregory R. Pond et al. EUROPEAN UROLOGY
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer
- (2013) Carlo Buonerba et al. Future Oncology
- Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
- (2013) S. Halabi et al. JNCI-Journal of the National Cancer Institute
- Castration-Resistant Prostate Cancer: AUA Guideline
- (2013) Michael S. Cookson et al. JOURNAL OF UROLOGY
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
- (2013) David I Quinn et al. LANCET ONCOLOGY
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
- (2013) Pirkko-Liisa Kellokumpu-Lehtinen et al. LANCET ONCOLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting cell cycle and hormone receptor pathways in cancer
- (2013) C E S Comstock et al. ONCOGENE
- Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?
- (2013) Michael J. Morris et al. SEMINARS IN ONCOLOGY
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Potential use of custirsen to treat prostate cancer
- (2013) Celiste Higano OncoTargets and Therapy
- Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
- (2013) Frederik Birkebaek Thomsen et al. Scandinavian Journal of Urology
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
- (2012) Jatinder Goyal et al. BJU INTERNATIONAL
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Regimens
- (2012) Pieternella Lugtenburg et al. Clinical Lymphoma Myeloma & Leukemia
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial
- (2012) P-L Kellokumpu-Lehtinen et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
- (2011) J. S. de Bono et al. ANNALS OF ONCOLOGY
- The use of estramustine phosphate in the modern management of advanced prostate cancer
- (2011) Vincent Ravery et al. BJU INTERNATIONAL
- Dasatinib combined with docetaxel for castration-resistant prostate cancer
- (2011) John C. Araujo et al. CANCER
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2011) Nicolas Mottet et al. EUROPEAN UROLOGY
- Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
- (2011) Gregory R. Pond et al. EUROPEAN UROLOGY
- Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401
- (2011) Arti Hurria et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
- (2011) M. Marin-Aguilera et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology
- (2010) Jean-Pierre Droz et al. BJU INTERNATIONAL
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
- (2009) L. Zhao et al. CANCER RESEARCH
- Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
- (2009) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
- (2009) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
- (2009) Kenji Kuroda et al. PROSTATE
- Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
- (2008) Mari Nakabayashi et al. BJU INTERNATIONAL
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now